Antonio López-Serrano

Chemoprevention of polyp recurrence with curcumin followed by silibinin in a case of multiple colorectal adenomas

Chemoprevention is a practical approach to reduce the risk of various cancers including colorectal cancer (CRC). The goal is to reduce the incidence of pre-neoplastic adenomatous polyps and prevent its progression to CRC. Curcumin and silibinin prevent intestinal polyp formation in mice. Curcumin sensitizes silymarin to exert synergistic anticancer activity in colon cancer cells. Patients presenting with multiple colorectal adenomatous polyps (MCRA) have a high lifetime risk for CRC. We present a 57-year-old man with MCRA, without deleterious germline APC or MYH mutations. Our patient had 54 polyps in the first colonoscopy, most of 3 to 8 mm and one of 20 mm with high grade dysplasia / adenocarcinoma. Four subsequent colonoscopies showed continuous development of adenomatous polyps treated by polypectomy for the most part and some with heat. After the treatment with curcumin for 3 months and a half followed by silibinin for 9 months, we find many less polyps than in the previous colonoscopies, going from the finding of 40 adenomas of 3-6 mm in the pre-treatment colonoscopy to 3 polyps after treatment.

Papel del digestólogo en el manejo del paciente obeso

Obesity is a highly prevalent disease worldwide, and one in which gastroenterologists can play an important role. Some digestive diseases are more common in obese patients, and preoperative evaluation may be required in some cases. Additionally, bariatric surgery can lead to digestive complications in the short and long term that require intervention, and endoscopic treatment can be an important factor in weight loss. The aim of this review is to highlight the role of the gastroenterologist in the management of obese patients who are either scheduled for or have undergone surgical or endoscopic treatment for obesity.

Mo1339 Nation-Wide Multicenter Prospective Validation of the New Severity Classifications of Acute Pancreatitis

G A A b st ra ct s Fig 1a: A summary of biochemicals seperated by those that reached statistical significance (p < 0.05) and those that were near significance (0.05 < p < 0.10) between cases (SAP) and controls (MAP) at each time point (1-3). Collectively, metabolites were more likely to be upregulated in cases, but normalized as the disease process resolved (T1: 209 upregulated, T3: 130 upregulated).{BR}Figure 1b: Summary of the time progression of metabolites within cases (SAP) compared to controls (MAP). Compared to controls, metabolites were more dysregulated with time in cases.